Chen Yuan1, Zhi Rong Qian1, Ana Babic1, Vicente Morales-Oyarvide1, Douglas A Rubinson1, Peter Kraft1, Kimmie Ng1, Ying Bao1, Edward L Giovannucci1, Shuji Ogino1, Meir J Stampfer1, John Michael Gaziano1, Howard D Sesso1, Julie E Buring1, Barbara B Cochrane1, Rowan T Chlebowski1, Linda G Snetselaar1, JoAnn E Manson1, Charles S Fuchs1, Brian M Wolpin2. 1. Chen Yuan, Zhi Rong Qian, Ana Babic, Vicente Morales-Oyarvide, Douglas A. Rubinson, Kimmie Ng, Shuji Ogino, Charles S. Fuchs, and Brian M. Wolpin, Dana-Farber Cancer Institute and Harvard Medical School; Peter Kraft, Edward L. Giovannucci, Shuji Ogino, Meir J. Stampfer, Howard D. Sesso, Julie E. Buring, and JoAnn E. Manson, Harvard School of Public Health; Ying Bao, Edward L. Giovannucci, Shuji Ogino, Meir J. Stampfer, John Michael Gaziano, Howard D. Sesso, JoAnn E. Manson, and Charles S. Fuchs, Brigham and Women's Hospital and Harvard Medical School; John Michael Gaziano, Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA; Barbara B. Cochrane, University of Washington School of Nursing, Seattle, WA; Rowan T. Chlebowski, Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles Medical Center, Torrance, CA; and Linda G. Snetselaar, University of Iowa College of Public Health, Iowa City, IA. 2. Chen Yuan, Zhi Rong Qian, Ana Babic, Vicente Morales-Oyarvide, Douglas A. Rubinson, Kimmie Ng, Shuji Ogino, Charles S. Fuchs, and Brian M. Wolpin, Dana-Farber Cancer Institute and Harvard Medical School; Peter Kraft, Edward L. Giovannucci, Shuji Ogino, Meir J. Stampfer, Howard D. Sesso, Julie E. Buring, and JoAnn E. Manson, Harvard School of Public Health; Ying Bao, Edward L. Giovannucci, Shuji Ogino, Meir J. Stampfer, John Michael Gaziano, Howard D. Sesso, JoAnn E. Manson, and Charles S. Fuchs, Brigham and Women's Hospital and Harvard Medical School; John Michael Gaziano, Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA; Barbara B. Cochrane, University of Washington School of Nursing, Seattle, WA; Rowan T. Chlebowski, Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles Medical Center, Torrance, CA; and Linda G. Snetselaar, University of Iowa College of Public Health, Iowa City, IA. bwolpin@partners.org.
Abstract
PURPOSE: Although vitamin D inhibits pancreatic cancer proliferation in laboratory models, the association of plasma 25-hydroxyvitamin D [25(OH)D] with patient survival is largely unexplored. PATIENTS AND METHODS: We analyzed survival among 493 patients from five prospective US cohorts who were diagnosed with pancreatic cancer from 1984 to 2008. We estimated hazard ratios (HRs) for death by plasma level of 25(OH)D (insufficient, < 20 ng/mL; relative insufficiency, 20 to < 30 ng/mL; sufficient ≥ 30 ng/mL) by using Cox proportional hazards regression models adjusted for age, cohort, race and ethnicity, smoking, diagnosis year, stage, and blood collection month. We also evaluated 30 tagging single-nucleotide polymorphisms in the vitamin D receptor gene, requiring P < .002 (0.05 divided by 30 genotyped variants) for statistical significance. RESULTS: Mean prediagnostic plasma level of 25(OH)D was 24.6 ng/mL, and 165 patients (33%) were vitamin D insufficient. Compared with patients with insufficient levels, multivariable-adjusted HRs for death were 0.79 (95% CI, 0.48 to 1.29) for patients with relative insufficiency and 0.66 (95% CI, 0.49 to 0.90) for patients with sufficient levels (P trend = .01). These results were unchanged after further adjustment for body mass index and history of diabetes (P trend = .02). The association was strongest among patients with blood collected within 5 years of diagnosis, with an HR of 0.58 (95% CI, 0.35 to 0.98) comparing patients with sufficient to patients with insufficient 25(OH)D levels. No single-nucleotide polymorphism at the vitamin D receptor gene met our corrected significance threshold of P < .002; rs7299460 was most strongly associated with survival (HR per minor allele, 0.80; 95% CI, 0.68 to 0.95; P = .01). CONCLUSION: We observed longer overall survival in patients with pancreatic cancer who had sufficient prediagnostic plasma levels of 25(OH)D.
PURPOSE: Although vitamin D inhibits pancreatic cancer proliferation in laboratory models, the association of plasma 25-hydroxyvitamin D [25(OH)D] with patient survival is largely unexplored. PATIENTS AND METHODS: We analyzed survival among 493 patients from five prospective US cohorts who were diagnosed with pancreatic cancer from 1984 to 2008. We estimated hazard ratios (HRs) for death by plasma level of 25(OH)D (insufficient, < 20 ng/mL; relative insufficiency, 20 to < 30 ng/mL; sufficient ≥ 30 ng/mL) by using Cox proportional hazards regression models adjusted for age, cohort, race and ethnicity, smoking, diagnosis year, stage, and blood collection month. We also evaluated 30 tagging single-nucleotide polymorphisms in the vitamin D receptor gene, requiring P < .002 (0.05 divided by 30 genotyped variants) for statistical significance. RESULTS: Mean prediagnostic plasma level of 25(OH)D was 24.6 ng/mL, and 165 patients (33%) were vitamin Dinsufficient. Compared with patients with insufficient levels, multivariable-adjusted HRs for death were 0.79 (95% CI, 0.48 to 1.29) for patients with relative insufficiency and 0.66 (95% CI, 0.49 to 0.90) for patients with sufficient levels (P trend = .01). These results were unchanged after further adjustment for body mass index and history of diabetes (P trend = .02). The association was strongest among patients with blood collected within 5 years of diagnosis, with an HR of 0.58 (95% CI, 0.35 to 0.98) comparing patients with sufficient to patients with insufficient 25(OH)D levels. No single-nucleotide polymorphism at the vitamin D receptor gene met our corrected significance threshold of P < .002; rs7299460 was most strongly associated with survival (HR per minor allele, 0.80; 95% CI, 0.68 to 0.95; P = .01). CONCLUSION: We observed longer overall survival in patients with pancreatic cancer who had sufficient prediagnostic plasma levels of 25(OH)D.
Authors: Brian M Wolpin; Kimmie Ng; Ying Bao; Peter Kraft; Meir J Stampfer; Dominique S Michaud; Jing Ma; Julie E Buring; Howard D Sesso; I-Min Lee; Nader Rifai; Barbara B Cochrane; Jean Wactawski-Wende; Rowan T Chlebowski; Walter C Willett; JoAnn E Manson; Edward L Giovannucci; Charles S Fuchs Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-11-15 Impact factor: 4.254
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: W A Ghali; H Quan; R Brant; G van Melle; C M Norris; P D Faris; P D Galbraith; M L Knudtson Journal: JAMA Date: 2001-09-26 Impact factor: 56.272
Authors: Gary G Schwartz; Dawn Eads; Anuradha Rao; Scott D Cramer; Mark C Willingham; Tai C Chen; Daniel P Jamieson; Lilin Wang; Kerry L Burnstein; Michael F Holick; Constantinos Koumenis Journal: Carcinogenesis Date: 2004-01-23 Impact factor: 4.944
Authors: Chen Yuan; Ying Bao; Chen Wu; Peter Kraft; Shuji Ogino; Kimmie Ng; Zhi Rong Qian; Douglas A Rubinson; Meir J Stampfer; Edward L Giovannucci; Brian M Wolpin Journal: J Clin Oncol Date: 2013-10-21 Impact factor: 44.544
Authors: Jared R Mayers; Chen Wu; Clary B Clish; Peter Kraft; Margaret E Torrence; Brian P Fiske; Chen Yuan; Ying Bao; Mary K Townsend; Shelley S Tworoger; Shawn M Davidson; Thales Papagiannakopoulos; Annan Yang; Talya L Dayton; Shuji Ogino; Meir J Stampfer; Edward L Giovannucci; Zhi Rong Qian; Douglas A Rubinson; Jing Ma; Howard D Sesso; John Michael Gaziano; Barbara B Cochrane; Simin Liu; Jean Wactawski-Wende; JoAnn E Manson; Michael N Pollak; Alec C Kimmelman; Amanda Souza; Kerry Pierce; Thomas J Wang; Robert E Gerszten; Charles S Fuchs; Matthew G Vander Heiden; Brian M Wolpin Journal: Nat Med Date: 2014-09-28 Impact factor: 53.440
Authors: Tsuyoshi Hamada; Chen Yuan; Shuji Ogino; Brian M Wolpin; Ying Bao; Mingfeng Zhang; Natalia Khalaf; Ana Babic; Vicente Morales-Oyarvide; Barbara B Cochrane; J Michael Gaziano; Edward L Giovannucci; Peter Kraft; JoAnn E Manson; Kimmie Ng; Jonathan A Nowak; Thomas E Rohan; Howard D Sesso; Meir J Stampfer; Laufey T Amundadottir; Charles S Fuchs; Immaculata De Vivo Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-08-19 Impact factor: 4.254
Authors: Dan Xi; Ting Bao; Qi Chen; Sushing Chen; Yung-Chi Cheng; Joseph Cullen; David A Frank; Jonathan W Friedberg; Ian Kronish; Jeffrey E Lee; Mark Levine; Pingping Li; Shao Li; Weidong Lu; Jun J Mao; Stephen O'Keefe; Larry Rubinstein; Manish A Shah; Leanna Standish; Channing J Paller; Edward Chu Journal: J Natl Cancer Inst Monogr Date: 2017-11-01
Authors: Elizabeth Loehrer; Rebecca A Betensky; Edward Giovannucci; Li Su; Andrea Shafer; Bruce W Hollis; David C Christiani Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-06-11 Impact factor: 4.254
Authors: Daniel D Von Hoff; Derek Cridebring; Olivia Yu Tian; Haiyong Han; Rafia Bhore; Twyla Franco; Michael S Ondovik; Chrystal U Louis Journal: Oncologist Date: 2021-01-11
Authors: David J Cote; Stephanie A Smith-Warner; Jordan H Creed; Jeremy Furtado; Travis Gerke; Molin Wang; Youngchul Kim; Meir J Stampfer; Kathleen M Egan Journal: Cancer Causes Control Date: 2021-01-23 Impact factor: 2.506
Authors: P G Vaughan-Shaw; F O'Sullivan; S M Farrington; E Theodoratou; H Campbell; M G Dunlop; L Zgaga Journal: Br J Cancer Date: 2017-03-16 Impact factor: 7.640